Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel

Background: androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study....

Descripción completa

Detalles Bibliográficos
Autores: Jiménez, Natalia, Reig, Òscar, Marín-Aguilera, Mercedes, Aversa, Caterina, Ferrer-Mileo, Laura, Font, Albert, Rodriguez-Vida, Alejo, Climent, Miguel Ángel, Cros, Sara, Chirivella, Isabel, Doménech, Montserrat, Figols, Mariona, González-Billalabeitia, Enrique, Jiménez Peralta, Daniel, Rodríguez-Carunchio, Leonardo, García-Esteve, Samuel, García de Herreros, Marta, Ribal, María José, Prat, Aleix, Mellado, Begoña
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/55438
Acceso en línea:http://hdl.handle.net/10230/55438
http://dx.doi.org/10.3390/cancers14194757
Access Level:acceso abierto
Palabra clave:Androgen receptor
Chemotherapy
Estrogen receptor
Hormonal therapy
Metastatic prostate cancer
Predictive biomarkers
Tumor suppressor genes
id ES_e4ab30b53ced33b94edd5ae8a62728e2
oai_identifier_str oai:recercat.cat:10230/55438
network_acronym_str ES
network_name_str España
repository_id_str
spelling Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxelJiménez, NataliaReig, ÒscarMarín-Aguilera, MercedesAversa, CaterinaFerrer-Mileo, LauraFont, AlbertRodriguez-Vida, AlejoCliment, Miguel ÁngelCros, SaraChirivella, IsabelDoménech, MontserratFigols, MarionaGonzález-Billalabeitia, EnriqueJiménez Peralta, DanielRodríguez-Carunchio, LeonardoGarcía-Esteve, SamuelGarcía de Herreros, MartaRibal, María JoséPrat, AleixMellado, BegoñaAndrogen receptorChemotherapyEstrogen receptorHormonal therapyMetastatic prostate cancerPredictive biomarkersTumor suppressor genesBackground: androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.MDPI202320232022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/55438http://dx.doi.org/10.3390/cancers14194757reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCopyright © 2022 by Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, et al. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/554382026-05-29T05:05:01Z
dc.title.none.fl_str_mv Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
title Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
spellingShingle Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
Jiménez, Natalia
Androgen receptor
Chemotherapy
Estrogen receptor
Hormonal therapy
Metastatic prostate cancer
Predictive biomarkers
Tumor suppressor genes
title_short Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
title_full Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
title_fullStr Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
title_full_unstemmed Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
title_sort Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
dc.creator.none.fl_str_mv Jiménez, Natalia
Reig, Òscar
Marín-Aguilera, Mercedes
Aversa, Caterina
Ferrer-Mileo, Laura
Font, Albert
Rodriguez-Vida, Alejo
Climent, Miguel Ángel
Cros, Sara
Chirivella, Isabel
Doménech, Montserrat
Figols, Mariona
González-Billalabeitia, Enrique
Jiménez Peralta, Daniel
Rodríguez-Carunchio, Leonardo
García-Esteve, Samuel
García de Herreros, Marta
Ribal, María José
Prat, Aleix
Mellado, Begoña
author Jiménez, Natalia
author_facet Jiménez, Natalia
Reig, Òscar
Marín-Aguilera, Mercedes
Aversa, Caterina
Ferrer-Mileo, Laura
Font, Albert
Rodriguez-Vida, Alejo
Climent, Miguel Ángel
Cros, Sara
Chirivella, Isabel
Doménech, Montserrat
Figols, Mariona
González-Billalabeitia, Enrique
Jiménez Peralta, Daniel
Rodríguez-Carunchio, Leonardo
García-Esteve, Samuel
García de Herreros, Marta
Ribal, María José
Prat, Aleix
Mellado, Begoña
author_role author
author2 Reig, Òscar
Marín-Aguilera, Mercedes
Aversa, Caterina
Ferrer-Mileo, Laura
Font, Albert
Rodriguez-Vida, Alejo
Climent, Miguel Ángel
Cros, Sara
Chirivella, Isabel
Doménech, Montserrat
Figols, Mariona
González-Billalabeitia, Enrique
Jiménez Peralta, Daniel
Rodríguez-Carunchio, Leonardo
García-Esteve, Samuel
García de Herreros, Marta
Ribal, María José
Prat, Aleix
Mellado, Begoña
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Androgen receptor
Chemotherapy
Estrogen receptor
Hormonal therapy
Metastatic prostate cancer
Predictive biomarkers
Tumor suppressor genes
topic Androgen receptor
Chemotherapy
Estrogen receptor
Hormonal therapy
Metastatic prostate cancer
Predictive biomarkers
Tumor suppressor genes
description Background: androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/55438
http://dx.doi.org/10.3390/cancers14194757
url http://hdl.handle.net/10230/55438
http://dx.doi.org/10.3390/cancers14194757
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422611983761408
score 15,811543

Similares en LA Referencia